mRNA |
selumetinib:UNC0638 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.071 |
0.04 |
mRNA |
linifanib |
CTRPv2 |
pan-cancer |
AAC |
0.071 |
0.04 |
mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.065 |
0.04 |
mRNA |
AZD6244 |
CTRPv2 |
pan-cancer |
AAC |
-0.07 |
0.04 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.065 |
0.05 |
mRNA |
etoposide |
CTRPv2 |
pan-cancer |
AAC |
0.057 |
0.05 |
mRNA |
Nilotinib |
CTRPv2 |
pan-cancer |
AAC |
-0.07 |
0.05 |
mRNA |
Doxorubicin |
gCSI |
pan-cancer |
AAC |
0.096 |
0.05 |
mRNA |
decitabine |
CTRPv2 |
pan-cancer |
AAC |
-0.05 |
0.06 |
mRNA |
importazole |
CTRPv2 |
pan-cancer |
AAC |
-0.07 |
0.06 |